Early careers Early careers At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
NexGard COMBO for cats EMA marketing authorization NexGard COMBO for cats EMA marketing authorization Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
Celebrating Women in Technology Celebrating Women in Technology We want to elevate women in technology: empower them, affirm their potential and enable them to soar to new heights
Innovation from within Innovation from within Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Phase II results cognitive impairment schizophrenia Phase II results cognitive impairment schizophrenia Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
DiaTEC new purification technology Ingelvac CircoFLEX DiaTEC new purification technology Ingelvac CircoFLEX Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Advance study vaccinating increased milk production Advance study vaccinating increased milk production [New ADVANCE study shows vaccinating with Bovela® results in increased milk production
collaboration-proxygen-molecular-glue-degraders collaboration-proxygen-molecular-glue-degraders Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Aservo EquiHaler wins Pharmapack Award 2021 Aservo EquiHaler wins Pharmapack Award 2021 Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
global-top-employer global-top-employer For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Sabine Reinig Sabine Reinig For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
PREVEXXION® RN: Marek’s disease vaccine available in EU UK PREVEXXION® RN: Marek’s disease vaccine available in EU UK Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
Boehringer Ingelheim good 2021 business performance Boehringer Ingelheim good 2021 business performance 2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Boehringer Ingelheim attends WVPAC 2019 Boehringer Ingelheim attends WVPAC 2019 Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Classical Swine Fever live vaccine approved in China Classical Swine Fever live vaccine approved in China Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Accelerating new cancer medicines in partnership with CBmed Accelerating new cancer medicines in partnership with CBmed Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU